Table 1

Baseline demographics, disease and clinical characteristics by line-of-treatment category
Demographic characteristics N First-line n = 118 Second-line n = 996 Overall n = 1114
Age, mean (SD) 1113 59.1 (13.7) 56.2 (12.4) 56.5 (12.6)
Female, n (%) 1114 82 (69.5) 822 (82.5) 904 (81.1)
Weight, mean (SD) 1102 75.5 (15.9) 74.5 (17.0) 74.6 (16.9)
Disease characteristics
Mean disease duration, years (SD) 1079 6.9 (7.7) 11.5 (8.9) 11.0 (8.9)
Disease duration, n (%)
≤2 years 41 (35.3) 100 (10.4) 141 (13.1)
3–5 years 30 (25.9) 200 (20.8) 230 (21.3)
6–10 years 21 (18.1) 242 (25.1) 263 (24.4)
>10 years 24 (20.7) 421 (43.7) 445 (41.2)
Previous treatments
Previously treated with biologic agents, n (%) 1114 0 (0.0) 996 (100) 996 (89.4)
At least one anti-TNF agent, n (%) 0 (0.0) 978 (98.2) 978 (87.8)
Anti-TNF only 0 (0.0) 790 (79.3) 790 (70.9)
Anti-TNF and another biologic 0 (0.0) 188 (18.9) 188 (16.9)
Other mechanisms of action only 0 (0.0) 18 (1.8) 18 (1.6)
Number of prior anti-TNF agents, mean (SD) 0 (0.0) 1.6 (0.7) 1.4 (0.8)
One, n (%) 0 (0.0) 480 (48.2) 480 (43.1)
Two, n (%) 0 (0.0) 405 (40.7) 405 (36.4)
Three, n (%) 0 (0.0) 93 (9.3) 93 (8.3)
Clinical characteristics N* First-line N = 111 Second-line N = 968 Overall N = 1079
Tender joint count (28), mean (SD) 1052 11.5 (7.3) 11.4 (7.3) 11.4 (7.3)
Swollen joint count (28), mean (SD) 1069 9.5 (5.8) 7.8 (5.8) 8.0 (5.9)
Patient global assessment, mean (SD) (VAS 100 mm) 1002 61.9 (22.1) 66.2 (20.1) 65.8 (20.3)
Physician global assessment, mean (SD) (VAS 100 mm) 937 61.9 (18.7) 61.8 (19.4) 61.8 (19.3)
Patient global assessment of pain, mean (SD) (VAS 100 mm) 990 59.9 (24.5) 65.9 (20.7) 65.3 (21.1)
Patients with erosions, n (%) 926 58 (58.0) 590 (71.4) 648 (70.0)
DAS28 (ESR), mean (SD) 748 5.5 (1.3) 5.6 (1.2) 5.6 (1.2)
DAS28 (CRP), mean (SD) 216 4.8 (1.1) 5.2 (1.3) 5.2 (1.3)
CDAI, mean (SD) 919 33.4 (13.1) 31.5 (13.0) 31.7 (13.0)
SDAI, mean (SD) 824 35.4 (13.8) 33.9 (13.8) 34.0 (13.8)
HAQ-DI, mean (SD) 988 1.42 (0.59) 1.56 (0.67) 1.55 (0.67)
CRP mg/L, mean (SD) 943 19.6 (32.5) 24.4 (40.6) 23.9 (39.9)
ESR mm/hour, mean (SD) 988 32.5 (23.6) 35.5 (24.5) 35.2 (24.4)
Rheumatoid factor positive, n (%) 886 64 (68.1) 549 (69.3) 613 (69.2)
Anti-CCP positive, n (%) 598 36 (59.0) 354 (65.9) 390 (65.2)

*All patients with relevant baseline data assessed no later than 8 days after the first infusion of abatacept.

CCP, anti-cyclic citrullinated protein; CDAI, Clinical Disease Activity Index; CRP, C-reactive protein; DAS28, Disease Activity Score 28; ESR, erythrocyte sedimentation rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; SD, standard deviation; SDAI, Simplified Disease Activity Index; TNF, tumor necrosis factor; VAS, visual analog scale.

Nüßlein et al.

Nüßlein et al. BMC Musculoskeletal Disorders 2014 15:14   doi:10.1186/1471-2474-15-14

Open Data